Abstract：
BACKGROUND: The in vitro cultivation of human noroviruses allows a comparison of antibody levels measured in neutralization and histoblood group antigen (HBGA)-blocking assays.
METHODS: Serum samples collected during the evaluation of an investigational norovirus vaccine (HIL-214 [formerly TAK-214]) were assayed for neutralizing antibody levels against the vaccine\'s prototype Norwalk virus/GI.1 (P1) virus strain. Results were compared to those previously determined using HBGA-blocking assays.
RESULTS: Neutralizing antibody seroresponses were observed in 83% of 24 vaccinated adults, and antibody levels were highly correlated (r=0.81, P<0.001) with those measured by HBGA-blocking.
CONCLUSIONS: GI.1-specific HBGA-blocking antibodies are a surrogate for neutralization of GI.1 norovirus.
METHODS: Serum samples collected during the evaluation of an investigational norovirus vaccine (HIL-214 [formerly TAK-214]) were assayed for neutralizing antibody levels against the vaccine\'s prototype Norwalk virus/GI.1 (P1) virus strain. Results were compared to those previously determined using HBGA-blocking assays.
RESULTS: Neutralizing antibody seroresponses were observed in 83% of 24 vaccinated adults, and antibody levels were highly correlated (r=0.81, P<0.001) with those measured by HBGA-blocking.
CONCLUSIONS: GI.1-specific HBGA-blocking antibodies are a surrogate for neutralization of GI.1 norovirus.
摘要：
背景：人诺如病毒的体外培养可以比较中和和组织基因组抗原（HBGA）阻断测定中测量的抗体水平。
方法：在评价一种研究性诺如病毒疫苗（HIL-214[以前称为TAK-214]）期间收集的血清样本，测定针对该疫苗原型诺沃克病毒/GI.1(P1)病毒株的中和抗体水平。将结果与先前使用HBGA阻断测定确定的结果进行比较。
结果：在24名接种疫苗的成年人中，有83％观察到中和抗体血清反应，和抗体水平高度相关（r=0.81，P<0.001）与HBGA阻断测量。
结论：GI.1特异性HBGA阻断抗体是GI.1诺如病毒中和的替代品。
方法：在评价一种研究性诺如病毒疫苗（HIL-214[以前称为TAK-214]）期间收集的血清样本，测定针对该疫苗原型诺沃克病毒/GI.1(P1)病毒株的中和抗体水平。将结果与先前使用HBGA阻断测定确定的结果进行比较。
结果：在24名接种疫苗的成年人中，有83％观察到中和抗体血清反应，和抗体水平高度相关（r=0.81，P<0.001）与HBGA阻断测量。
结论：GI.1特异性HBGA阻断抗体是GI.1诺如病毒中和的替代品。
